![Hoe eenvoudige semantiek onze AI-citaties met 642% verhoogde [Nieuwe resultaten]](https://www.pharmamarketeer.nl/wp-content/uploads/2026/01/719-370x300.jpg)
AstraZeneca’s PARP inhibitor Lynparza was successful in improving progression free survival in a Phase 3 trial of patients with metastatic prostate cancer. The drug met its primary endpoint in the Phase 3 PROfound...
European approval for two new delivery formulations of GSK’s Nucala in severe eosinophilic asthma
Following closely on the heels of the news that its deal to merge Pfizer’s consumer health business with its own, GSK has announced that Nucala (mepolizumab) had secured approval from the European Commission for two new...
Sanofi’s Dupixent extended in Europe to cover adolescents in atopic dermatits
Sanofi has announced that European Commission (EC) has chosen to extend the marketing approval of its interleukin-4 (IL-4) and interleukin-13 (IL-13) inhibitor Dupixent (dupilumab) to cover the treatment of adolescent...
EMA committee recommends approval of Merck’s Zerbaxa 3g dose to treat adults with HAP, including VAP
Merck, known as MSD outside the United States and Canada, announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending...
Sanofi’s Dupixent improves skin clearance in paediatric atopic dermatitis
As the therapy secured approval in Europe for treatment of adolescent patients with moderate-to-severe atopic dermatitis, Sanofi has revealed new Phase 3 data for Dupixent (dupilimab) in the treatment of severe atopic...
NICE recommends Pierre Fabre’s Nerlynx in adjuvant HER2+ breast cancer
Pierre Fabre’s Nerlynx (neratinib) has been recommended by NICE as a new option for NHS patients with early hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-positive breast cancer. The ruling...
How to Match Your Content to the Best Distribution Channel
If you don’t distribute your content smartly, you’ll never achieve your brand’s content marketing goals. But how do you know which are the best channels based on your goals and audience? This succinct guide will help...
‘Marketing equals overhead’: Why marketing is still seen as a cost-center
Despite chief marketing officers making the case for how important marketing is to an overall business, marketing’s reputation as a “cost center,” versus one that actually drives profits, is hard to shake off. Earlier...
Lilly’s Verzenio combo shows additional breast cancer survival benefit in new Phase 3 data
Eli Lilly has revealed new Phase 3 data on its CDK4 & 6 inhibitor Verzenio (abemaciclib), demonstrating its efficacy in extending overall survival when combined with AstraZeneca’s Faslodex (fulvestrant) in the...
Biogen & Alkermes’ multiple sclerosis drug proves ‘statistically superior’ to Tecfidera at Phase 3
Biogen and Alkermes have unveiled new Phase 3 data for diroximel fumarate, comparing the adequacy of the therapy to Biogen’s own Tecfidera (dimethyl fumarate) in the treatment of patients with relapsing-remitting...
Sensyne Health and Bayer sign collaboration agreement to accelerate cardiovascular drug development
Sensyne Health plc, the British clinical AI technology company, today announces that it has signed an initial two-year collaboration agreement with Bayer to accelerate the clinical development of new treatments for...
ViiV seeks EU marketing nod for cabotegravir in combo with rilpivirine as first monthly, injectable treatment for HIV
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, announced the submission of a marketing authorisation application (MAA) to the
European Commission approves Bristol─Myers Squibb’s pending acquisition of Celgene
Bristol─Myers Squibb Company announced that the European Commission (EC) has granted unconditional approval of Bristol─Myers Squibb’s pending acquisition of Celgene Corporation.
Retrophin receives US FDA approval for Thiola EC 100mg & 300mg tablets to treat cystinuria
Retrophin, Inc., announced that the US Food and Drug Administration (FDA) has approved 100 mg and 300 mg tablets of Thiola EC (tiopronin), a new enteric─coated formulation of Thiola (tiopronin)
Herbeoordeling middelen met cyproteron
Geneesmiddelen die het synthetische progestageen cyproteron bevatten worden opnieuw beoordeeld. Dit heeft de veiligheidscommissie van het Europees Geneesmiddel Agentschap (EMA), de Pharmacovigilance Risk Assessment...
Nipocalimab Gets Fast-Tracked for Hemolytic Disease of the Fetus and Newborn
The Food and Drug Administration (FDA) has granted Fast Track designation to nipocalimab (M281) for the prevention of hemolytic disease of the fetus and newborn (HDFN). HDFN is a blood disorder that occurs during...
For Better Results, Think of Content Marketing Like a Product
Your content marketing can’t achieve its potential if it’s structured as one project after another. Cleveland Clinic marketing leaders share how to give your content marketing a product-focused approach for bigger...
Smart Content Strategist Goes Way Beyond ‘Dummies’ for Salesforce (B2B CMY Finalist)
Heike Young creates content reflecting a research-driven, customer focus that fits in a cross-platform plan supported by employee engagement. Learn more about why this Salesforce content leader is a Content Marketer of...
